The role of race in heart failure therapy.
Heart failure in blacks is a unique malady characterized by a different natural history, more worrisome prognosis, and potential variances in the response to current medical therapy for heart failure. The overwhelming burden of hypertension as a putative cause of left ventricular dysfunction identifies this illness. Although differences in the response to medical therapy have been described, angiotensin-converting enzyme inhibitors and beta-blockers remain the most appropriate therapy. Certain genetic polymorphisms may exist that explain the observed differences.
Yancy
Clyde W
CW
Department of Internal Medicine/Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. clyde.yancy@utsouthwestern.edu
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D044383:Black People; D003324:Coronary Artery Disease / Q000150:complications / Q000453:epidemiology / Q000208:ethnology*; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000208:ethnology*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000453:epidemiology / Q000208:ethnology*; D015994:Incidence; D011379:Prognosis; D011412:Propanolamines / Q000627:therapeutic use; D044469:Racial Groups; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D018487:Ventricular Dysfunction, Left / Q000150:complications / Q000453:epidemiology / Q000208:ethnology* / Q000401:mortality
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D011412:Propanolamines; C024307:bucindolol